Trial Profile
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary)
- Indications Carcinoma; Chondrosarcoma; Endometrial cancer; Gastric cancer; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Shanghai Junshi Biosciences
- 12 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2023.
- 28 Sep 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2022.